Axsome TherapeuticsAXSM
AXSM
About: Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Employees: 589
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
210% more first-time investments, than exits
New positions opened: 90 | Existing positions closed: 29
37% more capital invested
Capital invested by funds: $3.15B [Q4 2024] → $4.32B (+$1.17B) [Q1 2025]
28% more call options, than puts
Call options by funds: $111M | Put options by funds: $86.5M
20% more funds holding
Funds holding: 290 [Q4 2024] → 348 (+58) [Q1 2025]
9% more funds holding in top 10
Funds holding in top 10: 11 [Q4 2024] → 12 (+1) [Q1 2025]
0.85% less ownership
Funds ownership: 76.71% [Q4 2024] → 75.86% (-0.85%) [Q1 2025]
11% less repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 114
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$150
46%
upside
Avg. target
$174
69%
upside
High target
$190
84%
upside
7 analyst ratings
7 positive
100%
0 neutral
0%
0 negative
0%
Morgan Stanley Sean Laaman | 84%upside $190 | Overweight Assumed | 3 Jul 2025 |
RBC Capital Leonid Timashev | 81%upside $186 | Outperform Maintained | 12 Jun 2025 |
HC Wainwright & Co. Raghuram Selvaraju | 75%upside $180 | Buy Reiterated | 10 Jun 2025 |
Needham Ami Fadia | 46%upside $150 | Buy Maintained | 9 Jun 2025 |
Oppenheimer Matthew Hershenhorn | 80%upside $185 | Outperform Initiated | 3 Jun 2025 |
Financial journalist opinion
Based on 6 articles about AXSM published over the past 30 days
Positive
Zacks Investment Research
1 day ago
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Positive
Seeking Alpha
4 days ago
Axsome: Some Recent Setbacks, Some Recent Wins -- Still A Buy
Axsome's valuation is driven by its promising pipeline, with Auvelity as a proven commercial success and Symbravo and AXS-12 showing solid potential. Recent setbacks include the FDA's refusal to file AXS-14 and Sunosi's failure in MDD studies, but ADHD data for Sunosi is encouraging. I estimate $3bn in peak revenues by the mid-2030s, which supports a Buy rating despite management's more ambitious projections.
Negative
The Motley Fool
6 days ago
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now
Should you invest in stocks right now? Some might be hesitant to do so because of the volatility broader equities have faced this year.
Neutral
GlobeNewsWire
1 week ago
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline
Comprehensive review of broad pipeline targeting Alzheimer's disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new data analyses
Neutral
GlobeNewsWire
3 weeks ago
Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4
NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the second quarter of 2025 on Monday, August 4, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update.
Neutral
GlobeNewsWire
3 weeks ago
Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21
NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will host its Frontiers in Brain Health R&D Day on July 21, 2025, starting at 11:00 a.m. Eastern Time in New York City. The event will highlight Axsome's singular, innovative late-stage CNS pipeline.
Neutral
GlobeNewsWire
1 month ago
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month
NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today is joining with the Alzheimer's disease advocacy community to raise awareness of the growing impact of Alzheimer's disease in the United States and the importance of brain health during this year's Alzheimer's & Brain Awareness Month.
Neutral
GlobeNewsWire
1 month ago
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced seven presentations, including two featured oral plenary sessions, on AXS-12 and solriamfetol, at SLEEP 2025, the 39th annual meeting of the Associated Professional Sleep Societies (APSS), being held June 8-11, 2025, in Seattle, Washington.
Positive
The Motley Fool
1 month ago
2 Soaring Stocks Wth More Upside Potential
Although fundamental investing wisdom tells us to "buy low," it may still be worthwhile to purchase shares of top companies following significant runs. Any point can be considered low -- even after massive gains -- provided there is plenty of upside left.
Negative
Zacks Investment Research
1 month ago
Why Is Axsome (AXSM) Down 1.8% Since Last Earnings Report?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Charts implemented using Lightweight Charts™